COMMUNIQUÉS West-GlobeNewswire

Smart Minimalism, Supreme Efficiency: CUKTECH 15 Charging Station Makes Its Debut in Malaysia
13/04/2026
KUALA LUMPUR, Malaysia, April 13, 2026 (GLOBE NEWSWIRE) -- CUKTECH, a global leader in intelligent power solutions, today announced the official Malaysian launch of its highly anticipated flagship: the CUKTECH 15 [...]
Boehringer Ingelheim introduces LENZELTA®: A new vaccine advancing mastitis prevention in dairy cows
13/04/2026
LENZELTA ® is a new vaccine significantly reducing the incidence and severity of clinical mastitis in vaccinated cows and heifers 1 . Administration is simple with two doses during the dry-off period. Mastitis continues [...]
Epitopea renforce son comité consultatif scientifique avec la nomination de Lisa Butterfield, figure de renom dans le domaine du cancer
13/04/2026
CAMBRIDGE, Royaume-Uni et MONTRÉAL, 13 avr. 2026 (GLOBE NEWSWIRE) -- Epitopea , une société transatlantique spécialisée dans l'immunothérapie contre le cancer qui développe des immunothérapies à base d'ARN accessibles [...]
Rising UK Dental Costs and NHS Access Crisis Drive Record Demand for Treatment in Türkiye — DentSpa Leads the Response
13/04/2026
ISTANBUL, April 13, 2026 (GLOBE NEWSWIRE) -- According to ad hoc data released by the ONS on 19 September 2025, approximately 523,000 UK residents now travel abroad annually for dental treatment — a 50.29% increase from [...]
Major Shareholder Announcement
13/04/2026
April 13, 2026 Company Announcement No. 8 Major Shareholder Announcement COPENHAGEN, DENMARK and BOSTON, MA, USA, 13 April 2026 – BioPorto A/S (“BioPorto” or the “Company”) (CPH: BIOPOR) hereby announces, pursuant to [...]
Epitopea Strengthens Scientific Advisory Board with Appointment of Leading Authority in Cancer, Lisa Butterfield
13/04/2026
CAMBRIDGE, United Kingdom and MONTREAL, April 13, 2026 (GLOBE NEWSWIRE) -- Epitopea , a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies for hard-to-treat [...]
Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)
13/04/2026
Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduced urticaria [...]
Data Published in Nature Communications Highlights Unique Mechanism of Action of Alpibectir in Combination with Ethionamide (AlpE)
13/04/2026
BASEL, Switzerland, April 13, 2026 (GLOBE NEWSWIRE) -- BioVersys and partners publish in the prestigious journal of Nature Communications pre-clinical development data of AlpE (alpibectir and ethionamide), an innovative [...]
SynOx Therapeutics Announces Positive Topline Results from the Phase 3 TANGENT Study, Supporting Emactuzumab as a Differentiated, Next-generation Treatment for Patients with Tenosynovial Giant Cell Tumor (TGCT)
13/04/2026
TANGENT met its primary and secondary endpoints with a high level of statistical significance vs. placebo at 6 months, including ORR by RECIST V1.1 and Tumor Volume Score (TVS), and clinically meaningful improvements in [...]
Communiqué de presse : Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants
13/04/2026
Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants L'approbation dans l'urticaire chronique spontanée (UCS) pour les enfants [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
13/04/2026
COPENHAGEN, Denmark, April 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up [...]
Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
13/04/2026
Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Approval in CSU for children two to 11 years of age is based on data from the [...]
Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis
13/04/2026
The Elecsys NfL blood test detects neuroaxonal damage associated with neuroinflammation in adults diagnosed with relapsing remitting multiple sclerosis. 1 This minimally invasive blood test enables greater patient [...]
Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia
13/04/2026
NBI-1117570 is an investigational oral, dual muscarinic M1/M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine Nxera to receive US [...]
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
11/04/2026
Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of heavily pre-treated patients with HER2-expressing, recurrent endometrial cancer [...]
NeuroSalt Under Investigation: What the 2026 Formulation Transparency Review Reveals About Botanical Ingredients, Dosage Disclosure, and Consumer Verification
11/04/2026
A detailed overview of NeuroSalt's five-ingredient plant-based nerve health supplement — covering botanical formula composition, ingredient-level research, dosage disclosure, 60-day refund policy, and the consumer [...]
Gentle Patches Claims Evaluated: 2026 Consumer Interest Rises Around Transdermal Wellness Patch Ingredients, Product Lineup, and Policy Transparency
11/04/2026
A timely 2026 release highlighting growing consumer research interest in skin-absorption wellness formats, ingredient themes, product variety, and publicly visible brand information across the Gentle Patches pill-free [...]
Glo & Spa-rkle Aesthetics and Medical Spa Unveils New State-of-the-Art Location in Lubbock, Texas
11/04/2026
Join the Grand Opening Celebration on May 1, 2026, for an Evening of Beauty and Innovation Lubbock, TX, April 10, 2026 (GLOBE NEWSWIRE) -- Glo & Spa-rkle Aesthetics and Medical Spa , a leader in aesthetic and [...]
Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026
10/04/2026
WALTHAM, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of [...]

Pages